Search
Tetrahydrocannabivarin
go.drugbank.com/drugs/DB11755InvestigationalAlthough THCV possesses an almost identical structure to Δ9-THC (varying only by the length of its lipophilic alkyl chain), it has different molecular targets and pharmacological profile [A32972]. … Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological
AG-702
go.drugbank.com/drugs/DB05836ExperimentalThis drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial. … HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms.
Genistein
go.drugbank.com/drugs/DB01645InvestigationalIt has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417]. … It has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode.
Categories: Estrogens, Non-SteroidalElafin
go.drugbank.com/drugs/DB05161InvestigationalElafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system. … Elafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in
Esmirtazapine
go.drugbank.com/drugs/DB06678InvestigationalEsmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause.
Pradefovir mesylate
go.drugbank.com/drugs/DB05478InvestigationalPradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. … As adefovir is poorly absorbed and associated with a high level of nephrotoxicity, pradefovir mesilate was designed to specifically target the liver and reduce risks to external tissue, especially the
XL765
go.drugbank.com/drugs/DB05241InvestigationalIt is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).
Anti-SARS-CoV-2 REGN-COV2
go.drugbank.com/drugs/DB15691InvestigationalAnti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. … These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.
Flurazepam
go.drugbank.com/drugs/DB00690ApprovedIllicitA benzodiazepine derivative used mainly as a hypnotic.